Focal therapy in localized prostate cancer: moving from therapeutic enthusiasm to structured stewardship

Focal therapy has emerged as a proposed middle path in localized prostate cancer, positioned between active surveillance and radical whole-gland treatment. Its appeal lies in treating the dominant clinically significant lesion while preserving uninvolved prostate tissue and adjacent structures important for urinary, sexual, and bowel function. However, this promise must be interpreted cautiously. Prostate cancer is frequently multifocal; imaging and biopsy can miss clinically significant disease, ablation margins cannot be examined in the same manner as surgical margins, and long-term comparative oncologic data remain less mature than those supporting established treatment strategies. This editorial argues that focal therapy should not be viewed as an unrestricted third standard or as a simple compromise between observation and radical treatment. Instead, its responsible use depends on structured stewardship: careful patient selection, concordant magnetic resonance imaging (MRI) and biopsy findings, transparent counseling about uncertainty, planned surveillance using prostate-specific antigen, imaging, and biopsy, and explicit salvage planning before treatment. Focal therapy may be most defensible in selected men with limited-volume, MRI-visible, clinically significant localized disease who understand the need for close follow-up and accept that further treatment may be required. The central question is therefore not only whether focal therapy is technically feasible, but whether the surrounding clinical pathway is sufficiently rigorous to protect oncologic safety while pursuing functional preservation.